medRxiv : the preprint server for health sciences · 2026
The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basallike and HER2-enriched breast cancer.
СтатьяПрепринтНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bernard Philip S, Chen Bingshu E, Gao Dongxia, Shepherd Lois E, Nielsen Torsten O, Varley Katherine E
Аннотация
PURPOSE: There are no clinically validated biomarkers to assess recurrence risk and guide treatment de-escalation in Basal-like and HER2-enriched breast cancer. Taxane-based chemotherapy remains a cornerstone of treatment despite significant toxicity. We evaluated the prognostic and predictive utility of the MHCII Immune Activation Score (IA Score) in these subtypes.
EXPERIMENTAL DESIGN: We retrospectively analyzed Basal-like and HER2-enriched breast cancers from the NCIC CTG MA.21 trial, which randomized patients with node-positive or high-risk node-negative disease to adjuvant chemotherapy with or without taxanes. MA.21 predated immune checkpoint inhibitors and routine HER2-targeted therapy. Subtype was previously assigned by PAM50. The 36-gene MHCII-IA assay used RNA from formalin-fixed, paraffin-embedded tissue. Multivariable Cox and Kaplan-Meier analyses evaluated associations between IA Score, clinicopathologic variables, tumor-infiltrating lymphocytes (TILs), relapse-free survival (RFS), and taxane benefit.
RESULTS: Among Basal-like (N=317) and HER2-enriched (N=155) tumors, higher IA Score was associated with improved RFS independent of lymph node status and provided stronger prognostic discrimination than TILs. Node-negative patients with high IA Score had excellent outcomes (8-year RFS >90%) versus those with low IA Score (8-year RFS <76%). In node-positive disease, high IA Score increased 8-year RFS by >10% relative to low IA Score. IA Score stratified taxane benefit: node-positive IA-low patients benefited, whereas IA-high tumors had favorable outcomes regardless of regimen.
CONCLUSIONS: MHCII Immune Activation Score is a prognostic and predictive biomarker in Basal-like and HER2-enriched breast cancer. High IA Score identified patients with excellent outcomes before pembrolizumab, trastuzumab, and taxane-based treatment escalation, providing a rationale for prospective risk-adapted de-escalation strategies.
EXPERIMENTAL DESIGN: We retrospectively analyzed Basal-like and HER2-enriched breast cancers from the NCIC CTG MA.21 trial, which randomized patients with node-positive or high-risk node-negative disease to adjuvant chemotherapy with or without taxanes. MA.21 predated immune checkpoint inhibitors and routine HER2-targeted therapy. Subtype was previously assigned by PAM50. The 36-gene MHCII-IA assay used RNA from formalin-fixed, paraffin-embedded tissue. Multivariable Cox and Kaplan-Meier analyses evaluated associations between IA Score, clinicopathologic variables, tumor-infiltrating lymphocytes (TILs), relapse-free survival (RFS), and taxane benefit.
RESULTS: Among Basal-like (N=317) and HER2-enriched (N=155) tumors, higher IA Score was associated with improved RFS independent of lymph node status and provided stronger prognostic discrimination than TILs. Node-negative patients with high IA Score had excellent outcomes (8-year RFS >90%) versus those with low IA Score (8-year RFS <76%). In node-positive disease, high IA Score increased 8-year RFS by >10% relative to low IA Score. IA Score stratified taxane benefit: node-positive IA-low patients benefited, whereas IA-high tumors had favorable outcomes regardless of regimen.
CONCLUSIONS: MHCII Immune Activation Score is a prognostic and predictive biomarker in Basal-like and HER2-enriched breast cancer. High IA Score identified patients with excellent outcomes before pembrolizumab, trastuzumab, and taxane-based treatment escalation, providing a rationale for prospective risk-adapted de-escalation strategies.